ATE295729T1 - Verwendung von einem mittel zur unterdrückung der infektion und der proliferation von hiv - Google Patents

Verwendung von einem mittel zur unterdrückung der infektion und der proliferation von hiv

Info

Publication number
ATE295729T1
ATE295729T1 AT02258095T AT02258095T ATE295729T1 AT E295729 T1 ATE295729 T1 AT E295729T1 AT 02258095 T AT02258095 T AT 02258095T AT 02258095 T AT02258095 T AT 02258095T AT E295729 T1 ATE295729 T1 AT E295729T1
Authority
AT
Austria
Prior art keywords
proliferation
infection
hiv
macrophage
human
Prior art date
Application number
AT02258095T
Other languages
English (en)
Inventor
Satoshi Omura
Kiyoko Akagawa
Toshiaki Sunazuka
Original Assignee
Kitasato Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kitasato Inst filed Critical Kitasato Inst
Application granted granted Critical
Publication of ATE295729T1 publication Critical patent/ATE295729T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Bidet-Like Cleaning Device And Other Flush Toilet Accessories (AREA)
AT02258095T 2002-03-07 2002-11-25 Verwendung von einem mittel zur unterdrückung der infektion und der proliferation von hiv ATE295729T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002061788 2002-03-07
JP2002261024A JP2003327536A (ja) 2002-03-07 2002-09-06 ヒト免疫不全症候群ウイルスの感染、増殖抑制剤

Publications (1)

Publication Number Publication Date
ATE295729T1 true ATE295729T1 (de) 2005-06-15

Family

ID=28043681

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02258095T ATE295729T1 (de) 2002-03-07 2002-11-25 Verwendung von einem mittel zur unterdrückung der infektion und der proliferation von hiv

Country Status (14)

Country Link
US (2) US7034005B2 (de)
EP (1) EP1350510B1 (de)
JP (1) JP2003327536A (de)
KR (1) KR20030074097A (de)
CN (1) CN1183915C (de)
AT (1) ATE295729T1 (de)
AU (1) AU2002302115B2 (de)
CA (1) CA2412065A1 (de)
DE (1) DE60204211T2 (de)
DK (1) DK1350510T3 (de)
ES (1) ES2241967T3 (de)
MX (1) MXPA02012320A (de)
PT (1) PT1350510E (de)
RU (1) RU2250770C2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009000393A (es) * 2006-07-13 2009-01-29 Eco Animal Health Ltd Uso de la tilvalosina como agente antiviral.
EP1911836A1 (de) * 2006-10-12 2008-04-16 AVIR Green Hills Biotechnology Trading GmbH Mediumzusatz für die Virusproduktion
GB0701253D0 (en) 2007-01-23 2007-02-28 Diagnostics For The Real World Nucleic acid amplification and testing
CA2808165A1 (en) 2010-08-18 2012-02-23 Universite Laval Compounds and therapeutic applications related to inhibition of dendritic cell immunoreceptor (dcir) activity and signaling events
MX2017003546A (es) * 2014-09-16 2017-08-14 Ubi Ip Holdings Tratamiento y curacion fucional de la infeccion por vih por anticuerpos monoclonales para cd4, que median la inhibicion competitiva de la entrada de vih.
KR20190071677A (ko) 2016-08-13 2019-06-24 유나이티드 바이오파마, 인크. Haart 안정화된 환자에서 cd4에 대한 항체에 의한 hiv 감염의 치료 및 지속적 바이러스 완화
CN110741011A (zh) * 2017-02-22 2020-01-31 免疫系统调节控股有限公司 新型免疫刺激大环内酯
CA3053993A1 (en) * 2017-02-22 2018-08-30 Immune System Regulation Holding Ab Novel immune stimulating compound
WO2018153954A1 (en) 2017-02-22 2018-08-30 Immune System Regulation Holding Ab Novel immune stimulating macrolide
JP7100652B2 (ja) 2017-02-22 2022-07-13 アイエスアール イミューン システム レギュレイション ホールディング アクチエボラグ（パブル） 新規免疫刺激マクロライド
CA3094747A1 (en) 2018-03-23 2019-09-26 ISR Immune System Regulation Holding AB (publ) Combinations of macrolide compounds and immune checkpoint inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0254534A3 (de) 1986-07-24 1991-04-17 William S. Robinson Erythromycin-Derivate und Zusammensetzungen und ihre Verwendung, um Virusreplikation und Krankheiten zu Inhibieren
US5106961A (en) * 1987-05-26 1992-04-21 Eli Lilly And Company Erythromycin ring-contracted derivatives
US5312837A (en) * 1991-01-29 1994-05-17 Genelabs Technologies, Inc. Method of treating viral infections with aryl macrocyclic compounds
US5541193A (en) 1991-09-05 1996-07-30 Abbott Laboratories Heterocycle-containing macrocyclic immunomodulators
FR2683723B1 (fr) 1991-11-14 1995-05-19 Mayoly Spindler Laboratoires Nouveaux medicaments antiviraux actifs sur le virus vih.
DE69400631T2 (de) * 1993-05-05 1997-02-27 Palo Alto Medical Foundation, Palo Alto, Calif. Verwendung von rifamycinderivaten zur herstellung eines arzneimittels zur behandlung der toxoplasmose
US5545734A (en) 1994-10-25 1996-08-13 Merck & Co., Inc. Aryl and heteroaryl macrolides having immunosuppressive activity
US6107327A (en) * 1996-08-30 2000-08-22 Eli Lilly And Company Therapeutic treatment for HIV infection
ME00189B (me) 1998-03-26 2011-02-10 Astellas Pharma Inc Preparati sa neprekidnim oslobađanjem
ATE321770T1 (de) * 2000-08-17 2006-04-15 Kitasato Inst Pseudoerythromycin-derivate

Also Published As

Publication number Publication date
KR20030074097A (ko) 2003-09-19
HK1056838A1 (en) 2004-03-05
CN1443538A (zh) 2003-09-24
DK1350510T3 (da) 2005-08-29
DE60204211D1 (de) 2005-06-23
CA2412065A1 (en) 2003-09-07
AU2002302115B2 (en) 2004-11-04
CN1183915C (zh) 2005-01-12
MXPA02012320A (es) 2004-12-13
US7034005B2 (en) 2006-04-25
JP2003327536A (ja) 2003-11-19
ES2241967T3 (es) 2005-11-01
EP1350510B1 (de) 2005-05-18
US20030186900A1 (en) 2003-10-02
DE60204211T2 (de) 2006-02-02
EP1350510A1 (de) 2003-10-08
US20060025357A1 (en) 2006-02-02
AU2002302115A1 (en) 2003-09-25
PT1350510E (pt) 2005-09-30
RU2250770C2 (ru) 2005-04-27

Similar Documents

Publication Publication Date Title
EP1385466A4 (de) Onkolytische virustherapie
BR0008840A (pt) Derivados de camptotecina tendo atividade antitumoral
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
ATE295729T1 (de) Verwendung von einem mittel zur unterdrückung der infektion und der proliferation von hiv
DE60336664D1 (de) Nichtnukleosidische reverse-transkriptase-hemmer
TR199903053T2 (xx) Benzimidazol t�revleri.
BR0010593A (pt) Terapia de combinação com antagonista de ccr5-interferon alfa peguilado para hiv
ATE264914T1 (de) Antivirale proteine, dafür kodierende dna, und deren verwendung
EP2548880A3 (de) Zusammensetzungen zur Erhöhung der Telomeraseaktivität
NO20073632L (no) Behandling av hepatitt C med interferon-beta i en asiatisk populasjon
MX2022009871A (es) Compuestos tetraciclicos para tratar la infeccion por el virus de la inmunodeficiencia humana (vih).
EA201100809A1 (ru) НОВЫЙ ФУНКЦИОНАЛЬНО АКТИВНЫЙ, ВЫСОКООЧИЩЕННЫЙ, СТАБИЛЬНЫЙ КОНЪЮГАТ ИНТЕРФЕРОНА АЛЬФА С ПОЛИЭТИЛЕНГЛИКОЛЕМ, ПРЕДСТАВЛЕННЫЙ ОДНИМ ПОЗИЦИОННЫМ ИЗОМЕРОМ ПЭГ-NαH-ИФН, С УМЕНЬШЕННОЙ ИММУНОГЕННОСТЬЮ, С ПРОЛОНГИРОВАННЫМ БИОЛОГИЧЕСКИМ ДЕЙСТВИЕМ, ПРИГОДНЫЙ ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ
BRPI0407140A (pt) Droga terapêutica para vìrus
CA2556829C (en) Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
HUP0300354A2 (hu) HIV immunadjuváns terápia
BR9915644A (pt) Uso de compostos de 17-cetoesteróides e seus derivados, metabolitos e precursores no tratamento de vìrus de hepatite c e outros togavìrus
WO2004033479A3 (en) Retroyclins: antiviral and antimicrobial peptides
ATE192926T1 (de) Flavopereirine enthaltende zusammensetzung und ihre anwendung in der behandlung gegen hiv-viren
DE602005013542D1 (de) Behandlung der oralen und darm mukositis durch verabreichung von menschlichem il-18
DK1404656T3 (da) Derivater af benzimidazol til behandling af sygdomme forbundet med en aktivering af mikroglia, såsom inflammatoriske, allergiske, inficerende eller autoimmune sygdomme
WO2006026604A3 (en) Methods for promoting wound healing
EA200501625A1 (ru) Интерферон-бета при тяжелом остром респираторном синдроме (sars)
BRPI0517401A (pt) tratamento ou prevenção de infecções hemorrágicas virais com compostos imunomoduladores
PT1150981E (pt) Composto nucleosidico terapeutico
DE60305018D1 (de) Citalopram zur behandlung von bluthochdruck

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1350510

Country of ref document: EP

REN Ceased due to non-payment of the annual fee